Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel
NASDAQ:ALZN

Alzamend Neuro 12/9/2025 Earnings Report

Alzamend Neuro logo
$1.03 +0.02 (+1.47%)
As of 02:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Alzamend Neuro EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.83
Beat/Miss
Beat by +$0.53
One Year Ago EPS
N/A

Alzamend Neuro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alzamend Neuro Announcement Details

Quarter
Date
12/9/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Alzamend Neuro's next earnings date is estimated for Tuesday, July 28, 2026, based on past reporting schedules.

Conference Call Resources

Alzamend Neuro Earnings Headlines

Alzamend Neuro Insider Trading Activity | NASDAQ:ALZN | Benzinga
May 1, 2026  |  benzinga.comhttps://www.benzinga.com/quote/ALZN/insider-trades
Alzamend Neuro (ALZN) price target decreased by 10.71% to 25.50
April 10, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/alzamend-neuro-alzn-price-target-decreased-by-10-71-to-25-50/ar-AA20uTnc
Your book attached
Veteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - at no charge. Inside, he reveals the one options technique that took him 11 years to find, why more strategies often lead to more losses, and the 10-minute nightly routine that replaced his 8-hour trading days.tc pixel
May 18 at 1:00 AM  |  Profits Run (Ad)
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
April 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/alzamend-neuro-reports-encouraging-pharmacodynamic-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-in-a-trial-conducted-at-massachusetts-general-hospital-302735711.html
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain ...
March 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/alzamend-neuro-reports-positive-topline-120000793.html
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
March 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/alzamend-neuro-reports-positive-topline-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-al001-achieves-bioequivalence-and-demonstrates-superior-brain-delivery-across-all-measured-brain-regions-302725991.html
See More Alzamend Neuro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email.

About Alzamend Neuro

Alzamend Neuro (NASDAQ:ALZN), an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

View Alzamend Neuro Profile
Earnings Tools